A new study provides an important proof-of-concept that viral replication can be substantially reduced for several weeks by a single injection of a tissue-targeted cellular microRNA antagonist, inhibiting a key component in a viral lifecycle. This result paves the way to the development of novel potent host-targeted antiviral approaches based on microRNA antagonism.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pasquinelli, A. E. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 13, 271–282 (2012).
Randall, G. et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl Acad. Sci. USA 104, 12884–12889 (2007).
Sarnow, P. & Sagan, S. M. Unraveling the mysterious interactions between hepatitis C virus RNA and liver-specific microRNA-122. Annu. Rev. Virol. 3, 309–332 (2016).
Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685–1694 (2013).
van der Ree, M. H. et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1b, double-blind, randomized controlled trial. Lancet 389, 709–717 (2017).
Prakash, T. P. et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796–8807 (2014).
Pawlotsky, J. M. What are the pros and cons of the use of host-targeted agents against hepatitis C? Antiviral Res. 105, 22–25 (2014).
Bai, S. et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 284, 32015–32027 (2009).
Tsai, W. C. et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884–2897 (2012).
Pawlotsky, J. M. Hepatitis C drugs: is next generation the last generation? Gastroenterology 151, 587–590 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.-M.P. has received research grants from Abbvie and Gilead. He has served as an adviser and speaker for Abbvie, Bristol-Myers Squibb, Gilead, Janssen and Merck.
Rights and permissions
About this article
Cite this article
Pawlotsky, JM. MicroRNA antagonists: promising antiviral agents against HCV and other viruses?. Nat Rev Gastroenterol Hepatol 14, 264–266 (2017). https://doi.org/10.1038/nrgastro.2017.28
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.28
